1. Introduction {#sec1-ijms-17-00265}
===============

Nutrition plays a key role in the life of every human being and can affect the quality of life in several ways. Nowadays, it is common knowledge that obesity and the risk to develop metabolic syndrome are correlated with either excessive or insufficient fetal nutrition \[[@B1-ijms-17-00265],[@B2-ijms-17-00265]\]. It is also important how the nutrition in neonates could affect their future life quality or could prevent the risk of chronic pathologies. The "thrifty phenotype hypothesis", by Hales *et al.* \[[@B3-ijms-17-00265]\] proposes an association among low birth weight and increased risk in adulthood of developing diseases, helping to understand how to treat these patients and to reach new qualitative and valid standards in the field of infant nutrition.

Newborns are classified as adequate for the gestational age (AGA), when the weight is between the 10th and 90th percentile, while neonates with a weight over the 90th percentile are defined as large for gestational age (LGA), and those below the 10th percentile are small for the gestational age. Neonates with an intrauterine growth restriction (IUGR) have at birth a weight or a body mass index lower than normal for the number of gestational weeks \[[@B4-ijms-17-00265]\]. Newborns belonging to the IUGR and LGA groups show a reduced carbohydrate tolerance with hypoglycemia \[[@B2-ijms-17-00265]\]; this condition can lead in adulthood to a higher risk of metabolic diseases, such as type 2 diabetes and obesity. Besides intra-uterine quality of nutrition, diet in the first weeks of life can determine the future life of newborns. A valid alternative to the recommended breastfeeding is the use of formula milk, and to assess the effects in neonate metabolism is of primary importance in the field of nutrition. A noninvasive way of targeting this issue is the study of the metabolite urine excretion of formula milk (FM) and breastfed (BM) individuals. In this regard, a gas-chromatography mass spectrometry (GC-MS) based metabolomics has proven to be a good analytical tool candidate. Metabolomics is a new field of research, based on the quantitative analysis, over time, of the metabolic changes of a living system to pathological and physiological stimuli and genetic modifications \[[@B5-ijms-17-00265]\]. This approach allowed evaluation of changes in neonate metabolism due to anthropometric parameters (IUGR and LGA) and nutrition \[[@B6-ijms-17-00265],[@B7-ijms-17-00265],[@B8-ijms-17-00265],[@B9-ijms-17-00265],[@B10-ijms-17-00265],[@B11-ijms-17-00265],[@B12-ijms-17-00265],[@B13-ijms-17-00265]\]. The aim of the present study, based on a GC-MS metabolomics approach, was to ascertain whether and to what extent different diet regimens affect the urine metabolite profiles of IUGR, AGA and LGA neonates fed exclusively with either human breast milk (BM) or with formula milk (FM).

2. Results {#sec2-ijms-17-00265}
==========

A total of 113 urine samples of AGA, IUGR and LGA neonates at T1 (at birth), T2 (three days) and T3 (seven days) were analysed by GC-MS. Representative chromatograms at T1 are shown in [Figure 1](#ijms-17-00265-f001){ref-type="fig"}.

From the analysis of the chromatograms, we observed 53 urine metabolites, such as short chain hydroxylated acids, long chain fatty acids, free amino acids, and mono- and disaccharides. Nineteen compounds were not identified and thereafter named U1--U19 ([Table 1](#ijms-17-00265-t001){ref-type="table"}).

To investigate similarities and differences among samples on the basis of their metabolite profiles, a multivariate approach was applied. For this purpose, we created a matrix composed of 94 samples and 53 variables (metabolites). First, to study sample distribution and to detect outliers or common features, we ran a principal component analysis (PCA) for T1, T2 and T3. Surprisingly, no sample clusterization was observed on the basis of sex or neonate weight (data not shown). At T1, the metabolite profiles of IUGR and LGA samples overlapped. For this reason, we decided to group IUGR and LGA samples in a single class and to compare it to AGA samples by a pair-wise orthogonal partial least square discriminant analysis (OPLS-DA). This discriminant analysis demonstrated that, at birth, urine of IUGR and LGA neonates have a different metabolite profile than AGA neonates (see score plot in [Figure 2](#ijms-17-00265-f002){ref-type="fig"}; R^2^Y = 0.71, Q^2^Y = 0.36).

From the analysis of the loading plot (data not shown) the most discriminating metabolites were: glucopyranoside, citric acid, and pyroglutamic acid for AGA, whilst threonic acid, pseudouridine and ribose for IUGR and LGA neonates. At T2 and T3, after feeding, IUGR and LGA cannot be differentiated from AGA. Therefore, we performed an OPLS-DA considering the urine of AGA, IUGR and LGA neonates at T2 and classifying them into two classes: breastfed and formula milk fed. A good discrimination was found between the two groups of neonates (R^2^Y = 0.81; Q^2^Y = 0.69) as shown in the score plot of [Figure 3](#ijms-17-00265-f003){ref-type="fig"}, with levels of glucose, galactose, and glycine higher in urine of neonates fed with FM, while aconitic acid, aminomalonic acid and adipic acid discriminated the BM diet.

For the two classes levels of these latter metabolites are reported in [Figure 4](#ijms-17-00265-f004){ref-type="fig"}. Other discriminant metabolites were *myo-*inositol, pseudouridine, citric acid and homoserine for FM, ribose for BM (data not shown).

The good performance of this model indicated a strong influence of diet in the urine metabolite profiles of neonates. A pair-wise OPLS-DA to the urine samples collected at T3 for BM *vs.* FM neonates was performed. This discriminant analysis (R^2^Y = 0.88, Q^2^Y = 0.61) indicated that also at T3 the diet strongly influenced urine metabolite profile. The score plot ([Figure 5](#ijms-17-00265-f005){ref-type="fig"}) shows that samples were correctly separated into two groups and that BM samples are more scattered than FM, highlighting in the former a higher intra-class variability.

By the analysis of loadings, we selected the most discriminant metabolites reported as box plot in [Figure 6](#ijms-17-00265-f006){ref-type="fig"}: pseudouridine, glycine and serine were up-regulated in the FM class, while 2-hydroxyglutaric acid, pyroglutamic and citric acid were up-regulated in the BM class. Other discriminant metabolites were threonine and *myo*-inositol for the FM class, while ribose, homoserine and oxalic acid for the BM class (data not shown).

3. Discussion {#sec3-ijms-17-00265}
=============

3.1. Discriminant Metabolites for the Different Feeding Regimes {#sec3dot1-ijms-17-00265}
---------------------------------------------------------------

In this study, urine samples of newborns fed exclusively with BM or exclusively with FM at T2 and T3 were collected and analyzed. After the shift of nutrient supply from placenta to milk, the metabolic profile of IUGR, AGA and LGA newborns was more affected by diet than by their anthropometric parameters. At T2 and T3 breastfed babies showed different urine metabolite profiles compared to those FM fed. The discriminant metabolites reflect the metabolic interactions between the neonates and their diet. Specifically, at T2 the up-regulated metabolites in FM fed neonates were glucose, galactose, glycine, pseudouridine, citric acid, *myo*-inositol, and homoserine. The higher levels of glucose and galactose measured in FM compared with breast milk together with the higher intestinal permeability of FM fed neonates can explain the higher excretion of these sugars in FM fed neonates \[[@B14-ijms-17-00265]\]. At T2, urine of neonates fed BM showed higher levels of aconitic acid, aminomalonic acid and adipic acid when compared to FM. The higher levels of adipic acid, probably reflect an elevated lipolysis and augmented catabolism of fatty acids in these neonates to compensate the low energy level of colostrum \[[@B15-ijms-17-00265],[@B16-ijms-17-00265]\]. This hypothesis can be also valid for aconitic acid that is a Krebs cycle compound. Aminomalonic acid is an amino dicarboxylic acid derived from cysteine and marker of oxidative stress \[[@B17-ijms-17-00265]\].

At T3, discriminant metabolites for FM fed were pseudouridine, glycine, serine, threonine, and *myo*-inositol. Noteworthy, newborns fed with FM shared the same representative metabolites (pseudouridine, *myo*-inositol and glycine) with IUGR and LGA neonates at birth, which raises questions about the quality of FM, especially when compared with BM. The benefits of breastfeeding are a topic of interest in medicine, involving different fields, from gynecology to pediatrics \[[@B18-ijms-17-00265]\]. It is well known that breastfeeding affects both mother and child positively \[[@B19-ijms-17-00265],[@B20-ijms-17-00265]\]. BM neonates were higher in pyroglutamic acid, a compound of the glutathione cycle, found up-regulated in AGA neonates at birth. Friesen *et al.* \[[@B21-ijms-17-00265]\] measured the plasma pyroglutamic acid levels in pregnant women and in their newborns finding that pyroglutamic acid was 56% elevated in pregnant women, and with higher levels in fetal plasma compared with maternal plasma \[[@B22-ijms-17-00265]\]. Jackson A. *et al.* \[[@B23-ijms-17-00265]\] reported that, when compared with adults, neonates excrete five to ten times the amount of pyroglutamic acid.

3.2. Maternal Malnutrition and Consequences on Neonates' Health {#sec3dot2-ijms-17-00265}
---------------------------------------------------------------

Several events may occur during intrauterine life, which could influence the future life of the fetus. In the case of IUGR neonates, maternal malnutrition, smoking and placental vascular disease are the main causes for not reaching full growth potential, with a lower body mass index and weight for the number of gestational weeks \[[@B24-ijms-17-00265],[@B25-ijms-17-00265]\]. On the other hand, macrosomia is characterized by an increased body mass index and weight above the 90th percentile for gestational age. The main risk factors are: maternal diabetes, obesity and nutrition/weight gain during pregnancy \[[@B26-ijms-17-00265]\].

Both fetal hyponutrition (IUGR) and hypernutrition (LGA) at birth can favor the developing of a low carbohydrate tolerance due to hypoglycemia. These findings can be strengthened by results of our study, in fact, the analysis of the samples collected in the first day of life revealed similarities between IUGR and LGA neonates when compared to AGA neonates, LGA and IUGR sharing the same up-regulated metabolites: threonic acid, pseudouridine, ribose, and, to a lesser extent, *myo*-inositol, and glycine. Lawson *et al.* \[[@B27-ijms-17-00265]\] reported that erythronic acid and threonic acid urine excretion was altered in adult individuals fed with synthetic diet rich of high carbohydrates.

In our statistical model, LGA and IUGR neonates at birth showed up-regulated threonic acid suggesting an altered carbohydrates metabolism. Recently, [d]{.smallcaps}-ribose has been found to be present at an abnormally high concentration in the urine of type 2 diabetics, suggesting a key role in metabolism carbohydrates disorders \[[@B28-ijms-17-00265]\]. Su *et al.* \[[@B28-ijms-17-00265]\] demonstrated that mouse spatial cognitive impairment is caused by ribose derived advanced glycation end products, partially proving a risk factor for IUGR neonates' cognitive dysfunction \[[@B29-ijms-17-00265],[@B30-ijms-17-00265]\]. Higher levels of glycine and *myo*-inositol in IUGR and LGA neonates were already observed in our recent works \[[@B31-ijms-17-00265],[@B32-ijms-17-00265]\]. The occurrence of *myo*-inositol in the urine is in accordance with the reduced carbohydrate tolerance due to the hypoglycemic and hyperglycemic status of IUGR and LGA neonates during the fetal life, and it should be considered as a marker of an altered glucose metabolism during fetal development \[[@B33-ijms-17-00265]\]. Moreover, newborns consume glycine to produce purines and heme, providing one third of the residues for the formation of collagen and elastin \[[@B34-ijms-17-00265]\], and is produced by the placenta in large amounts \[[@B23-ijms-17-00265],[@B26-ijms-17-00265]\]. Gannon *et al.* \[[@B35-ijms-17-00265]\] have demonstrated that the ingestion of glycine induced an increase of glucagon levels. Furthermore, when glycine is ingested with glucose, the insulin peak occurs later and is lower if compared to when glucose is ingested alone \[[@B35-ijms-17-00265]\].

Glycine plays also a key role in the synthesis of the glutathione (GSH), which is an intracellular scavenger of free radicals and reactive oxygen species. Numerous diseases in premature neonates, such as bronchopulmonary dysplasia, periventricular leukomalacia, intraventricular hemorrhage, retinopathy of prematurity and necrotizing enterocolitis have been associated to oxidative stress, decreased GSH, and free radical-mediated tissue injury \[[@B36-ijms-17-00265],[@B37-ijms-17-00265],[@B38-ijms-17-00265],[@B39-ijms-17-00265],[@B40-ijms-17-00265]\]. In presence of diabetes or high glucagon levels, the oxidation of glycine in hepatic cells increases and it may become a limiting factor in the synthesis of GSH \[[@B41-ijms-17-00265]\]. Different studies showed that glycine availability is able to limit erythrocyte GSH synthesis in burn patients \[[@B42-ijms-17-00265]\] or in malnourished children \[[@B43-ijms-17-00265]\]. Up-regulated urine levels of glycine in both IUGR and LGA neonates after birth may reflect the altered metabolic status of these infants, which appears to be predominantly catabolic, with a potential oxidative stress damage. Pseudouridine is an atypical nucleoside found in human urine as an RNA metabolite, specifically the degradation rate of rRNA was determined through the excretion of pseudouridine. Literature data suggest that the excretion rate of pseudouridine in healthy people is a valid non-invasive indicator of resting metabolic rate \[[@B44-ijms-17-00265]\]. From the evidence that pseudouridine inhibits basal glucose consumption in rat soleus muscle, Dzúrik *et al.* \[[@B45-ijms-17-00265]\] concluded that pseudouridine inhibits glucose use in the calcium modulation of the insulin regulatory cascade.

In the metabolic profile of AGA neonates, representative metabolites were glucopyranoside and organic acids such as citric acid, and benzoic acid. It has been postulated that urinary low molecular weight organic acid excretion in the neonate, which differs from the adult urinary pattern, suggests a reflection of the particular neonatal metabolism, including a high fatty acid use and a low protein catabolism \[[@B16-ijms-17-00265]\].

4. Experimental Section {#sec4-ijms-17-00265}
=======================

4.1. Subjects {#sec4dot1-ijms-17-00265}
-------------

This study was carried out on 113 urine samples from patients admitted to the Neonatal Intensive Care Unit, Puericulture Institute and Neonatal Section, Azienda Ospedaliera Universitaria, University of Cagliari (Cagliari, Italy) and to the Neonatal Intensive Unit and Neonatal Pathology of "S. Giovanni Calibita" Hospital Fatebenefratelli (Rome, Italy). The study protocol was approved by the local ethical committee and written informed consent was obtained from the parents before enrolment in the study (CA-206-18/03/2013). According to the anthropometric classification, neonates were divided in three groups: (1) AGA, *n* = 14 of which 6/8 males/females, mean gestational age 38.3 weeks, mean birth-weight (BW) 3033 ± 287 g (percentiles = 49.2); (2) IUGR, *n* = 10, 5/5 m/f, mean gestational age of 37 weeks, mean BW 2313 ± 365 g (percentiles = 6.9); (3) LGA, *n* = 11, 5/6 m/f, mean gestational age of 38.6 weeks, mean BW of 3858 ± 313 g (percentiles = 94.3). Urine samples were matched for sex, age, gestation and type of delivery, and were collected at different times: within 8 h of birth prior to the administration of food (first urine output) (T1), at the third day of life (T2) and at the seventh day of life (T3). The total number of samples collected was 31 for AGA (T1 = 14; T2 = 9; T3 = 8), 30 for IUGR (T1 = 10; T2 = 8; T3 = 12) and 33 (T1 = 11; T2 = 14; T3 = 8) for LGA. From T2, data regarding the infants' feeding regime were also collected, selecting only neonates fed exclusively with either FM or BM and excluding infants with mixed feeding (*n* = 19). At T2, 15 neonates of the studied population were fed with BM (7 AGA, 3 LGA, 5 IUGR) and 16 with FM (2 AGA, 11 LGA, 3 IUGR). At T3, 16 neonates were fed with BM (6 AGA, 6 LGA, 4 IUGR) and 12 with FM (2 AGA, 2 LGA, 8 IUGR). All the newborns survived. The clinical data of each patient was recorded in the hospital registers.

4.2. Chemicals {#sec4dot2-ijms-17-00265}
--------------

Chemicals, analytical standards and solvents were purchased from (Sigma Aldrich, Milano, Italy). Derivatized 2,2,3,3-d4-succinic acid was used as internal standard. Methoxyamine hydrochloride, *N*,*O*-bis(trimethylsilyl)trifluoroacetamide, trimethylchlorosilane (BSTFA + TMCS) were used for derivatization purposes.

4.3. Urine Samples Collection and Preparation {#sec4dot3-ijms-17-00265}
---------------------------------------------

Urine samples (2--3 mL) were collected using a non-invasive method with a ball of cotton, then aspirated with a syringe and transferred to a sterile 15 mL Falcon tube. The tubes were then stored at −80 °C. GC-MS, analyses were carried out at the Department of Life and Environmental Sciences laboratories in Cagliari. After thawing on ice, the urine samples were centrifuged for 10 min at 13,200 rpm. One hundred and fifty μL of supernatant from each sample were transferred to Eppendorf tubes containing 1 mg of urease, sonicated for 30 min at 37 °C and then centrifuged for 10 min at 13,200 rpm. The supernatant was separated and after drying derivatized with 50 μL of methoxyamine in pyridine solution (10 mg/mL). After 17 h, 100 μL of BSTFA + TMCS were added and after 1 h samples were resuspended with 600 μL of hexane. Trimethylsylilated 2,2,3,3-d4-succinic acid at 5 mg/L was used as internal standard.

4.4. GC-MS Analysis {#sec4dot4-ijms-17-00265}
-------------------

Analysis was conducted injecting one microliter of derivatized sample in a 6850 gas chromatograph attached with a 5973 Network mass spectrometer (Agilent Technologies, Santa Clara, CA, USA). GC separation was obtained with a 30 m × 0.25 mm ID, silica chemically bonded capillary column (J&W Scientific, Folsom, CA, USA). The temperature of the injector was 200 °C and the gas flow rate was 1 mL/min. The column initial temperature was mantained at 50 °C for 10 min and then increased to 300 °C at 10 °C/min and held at 300 °C for 10 min. The transfer line and the ion source temperatures were at 280 and 180 °C, respectively. Ions produced at 70 eV were recorded at 1.6 scan/s in the mass range *m*/*z* 50--550. GC-MS data analysis was conducted by integrating each resolved chromatogram peak and normalizing the area for the corrected total area of the chromatogram. Peaks were examined for their mass spectra and their identification was performed using the NIST08 library after deconvolution with an automated mass spectral deconvolution and identification system (AMDIS).

4.5. Multivariate Data Analysis {#sec4dot5-ijms-17-00265}
-------------------------------

A multivariate data analysis was performed using the SIMCA software (version 13.0, Umetrics, Umea, Sweden). Untargeted principal components analysis (PCA) was applied to visualize tendency of samples to cluster on the basis of similarities in their metabolite profile and to detect the presence of outliers. The latter can be detected by different tests, as implemented in SIMCA software. For sample classification and for the search of biomarkers that differentiate the predefined classes, the Orthogonal Partial Least Square-Discriminant Analysis (OPLS-DA) was performed, this is a supervised classification method that requires information about class membership of samples. In OPLS-DA, class separation is maximized in the predictive component (*x*-axis) and its orthogonal component (*y*-axis) express intra-class variability. The goodness of models was evaluated by the parameters: 3R^2^Y (goodness of classification) and Q^2^Y (goodness of classification in cross-validation) \[[@B46-ijms-17-00265]\].

5. Conclusions {#sec5-ijms-17-00265}
==============

In summary, our results show that at birth the urinary metabolome of AGA neonates differs from that of IUGR and LGA neonates, and that, when the nutrition supply moves from intrauterine to lactation or bottle feeding, the typology of milk (breast or formula) strongly characterize the urine metabolite profiles of neonates overcoming anthropometric classification. This confirmed the importance of quality of nutrition in the first days of life and also proves that this GC-MS based metabolomics approach is very sensitive to diet regimens and therefore endorses it as a helpful efficient tool in the research field of neonatal feeding. While published studies exist on milk metabolomics, this study, to our knowledge, the first report in literature, focuses on the different metabolic impacts that breast milk and formula milk display in infants of different categories (IUGR, AGA, LGA) in the first week of life. These data and ongoing studies on this topic may be very important from a practical point of view in selecting the formula milks that not only have physicochemical properties more similar to breast milk, but also determine metabolic and nutritional impacts similar to breast milk. We want to highlight the importance for neonates to consume breast milk when possible, and the need for the development of formula milk to more closely emulate breast milk. Future perinatal studies should also take into account an integration with maternal metabolic data.
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![Orthogonal partial least square discriminant analysis (OPLS-DA) of appropriate gestational age (AGA) *vs.* intrauterine growth restriction (IUGR) + large for gestational age (LGA) neonates at birth, R^2^Y = 0.71, Q^2^Y = 0.36. Score plot, triangles represent the AGA class, filled and empty circles LGA and IUGR, respectively. Separation of classes is maximized through the predictive component (*x*-axis), intraclass variability is described through the orthogonal component (*y*-axis).](ijms-17-00265-g002){#ijms-17-00265-f002}

![OPLS-DA of breast milk (BM) *vs.* formula milk (FM) fed neonates at T2, R^2^Y = 0.81 and Q^2^Y = 0.69. Score plot, triangles represent the AGA class, filled and empty circles LGA and IUGR, respectively. Black and grey colours represent BM and FM feeding, respectively. Separation of classes is maximized through the predictive component (*x*-axis), intraclass variability is described through the orthogonal component (*y*-axis).](ijms-17-00265-g003){#ijms-17-00265-f003}

![Comparison between the most discriminant metabolites. Box plots display the metabolite quantitative variation in each class.](ijms-17-00265-g004){#ijms-17-00265-f004}

![OPLS-DA of BM *vs.* FM neonates at T3, R^2^Y = 0.88 and Q^2^Y = 0.61. Score plot, triangles represent the AGA class, filled and empty circles LGA and IUGR, respectively. Black and grey colours represent BM and FM feeding, respectively.](ijms-17-00265-g005){#ijms-17-00265-f005}

![Comparison between most discriminant metabolites. Box plots display the metabolite quantitative variation in each class.](ijms-17-00265-g006){#ijms-17-00265-f006}

ijms-17-00265-t001_Table 1

###### 

Gas-chromatography mass spectrometry (GC-MS) characteristics of urine metabolites.

  Compound                             Rt (min)   EI-MS, *m*/*z* (amu) (% Relative Abundance)   Trivial Name                      Abbr
  ------------------------------------ ---------- --------------------------------------------- --------------------------------- --------
  Alanine                              16.72      116 (100), 73 (50), 147 (30)                  alanine                           ALA
  Glycine (2 TMS)                      17.14      102 (100), 73 (50), 147 (45)                  glycine (2 TMS)                   GLY2
  Oxalic acid                          17.48      147 (100), 73 (80), 133 (50)                  oxalic acid                       OXA
  3-Hydroxybutanoic acid               17.86      147 (100), 73 (50), 117 (45)                  3-hydroxybutyric acid             3HBA
  Benzoic acid                         19.36      179 (100), 105 (64), 135 (55)                 benzoic acid                      BA
  Glycine (3 TMS)                      20.23      174 (100), 73 (50), 248 (47)                  glycine (3 TMS)                   GLY3
  Butanedioic acid                     20.37      147 (100), 73 (50), 247 (45)                  succinic acid                     BUA
  2,3-Dihydroxypropanoic acid          20.54      171 (100), 100 (50), 292 (45)                 glyceric acid                     GLYA
  2,3-Dihydroxybutanoic acid           20.72      73 (100), 292 (50), 147 (45)                  2,3-dihydroxybutyric acid         DHB
  Serine                               20.99      204 (100), 73 (70), 218 (65)                  serine                            SER
  Threonine                            21.33      73 (100), 218 (94), 291 (50)                  threonine                         THR
  Unknown 1                            21.70      103 (100), 73 (90), 219 (60)                  U1                                
  3,4-Dihydroxybutanoic acid           21.97      73 (100), 233 (60), 147 (50)                  2-deoxytetronic acid              DOT A
  Homoserine                           22.21      218 (100), 73 (50), 128 (50)                  homoserine                        HOMO
  Aminomalonic acid                    22.49      147 (100), 73 (95), 218 (90)                  aminomalonic acid                 AMIN A
  Unknown 2                            22.57      158 (100), 68 (50), 147 (45)                  U2                                
  Unknown 3                            22.92      73 (100), 217 (90), 147 (80)                  U3                                
  Hexanedioic acid                     22.99      73 (100), 111 (68), 147 (50)                  adipic acid                       HA
  Aspartic acid                        23.12      232 (100), 73 (90), 100 (40)                  aspartic acid                     ASP A
  5-Oxo-1-proline                      23.19      156 (100), 73 (50), 147(40)                   pyroglutamic acid                 PYR A
  2,3,4-Trihydroxybutanoic acid        23.39      73 (100), 292 (90), 147 (50)                  threonic acid                     THR A
  2-Hydroxypentanedioic acid           23.80      129 (100), 147 (90), 247 (80)                 2-hydroxyglutaric acid            HGLU A
  Unknown 4                            24.34      73 (100), 231 (90), 147 (43)                  U4                                
  Phenylalanine                        24.46      333 (100), 73 (80), 218 (40)                  phenylalanine                     PHEN
  Unknown 5                            24.50      73 (100), 200 (80), 267 (70)                  U5                                
  Unknown 6                            24.79      73 (100), 103 (60), 217 (50)                  U6                                
  Ribose                               24.94      73 (100), 205 (50), 147 (40)                  ribose                            RIB
  Unknown 7                            25.08      73 (100), 147 (90), 247 (70)                  U7                                
  Xylitol                              25.44      73 (100), 217 (90), 307 (55)                  xylitol                           XYL
  Fucose                               25.5       117 (100), 73 (90), 217 (76)                  fucose                            FUC
  Unknown 8                            25.67      73 (100), 117 (90), 160 (30)                  U8                                
  1-Propene-1,2,3-tricarboxylic acid   25.83      73 (100), 147 (90), 229 (50)                  aconitic acid                     ACO A
  Unknown 9                            25.93      73 (100), 292 (70), 357 (40)                  U9                                
  1,2,3-Propanetricarboxylic acid      26.58      273 (100), 147 (60), 73 (60)                  citric acid                       CIT A
  Unknown 10                           26.93      73 (100), 217 (92), 147 (70)                  U10                               
  Galactose                            27.29      73 (100), 319 (90), 205 (60)                  galactose                         GAL
  Glucose                              27.52      73 (100), 319 (72), 205 (54)                  glucose                           GLU
  Unknown 11                           27.75      333 (100), 73 (58), 160 (43)                  U11                               
  Unknown 12                           28.04      373 (100), 73 (90), 358 (70)                  U12                               
  Hexadecanoic acid                    28.95      313 (100), 117 (90), 73 (90)                  palmitic acid                     HEX A
  Unknown 13                           29.16      73 (100), 103 (43), 244 (28)                  U13                               
  *Myo*-inositol                       29.29      305 (100), 217 (90), 73 (53)                  myoinositol                       MYO
  Octadecanoic acid                    30.75      341 (100), 205 (98), 117 (76)                 stearic acid                      OCT A
  Pseudouridine                        31.43      217 (100), 73 (50), 357 (40)                  pseudouridine                     PURID
  Unknonwn 14                          31.87      73 (100), 217 (50), 246 (49)                  U14                               
  Unknonwn 15                          32.01      217 (100), 73 (55), 147 (40)                  U15                               
  Unknonwn 16                          32.44      285 (100), 73 (55), 186 (40)                  U16                               
  2,3-Dihydroxy hexadecanoic acid      33.52      371 (100), 73 (40), 147 (40)                  2,3-dihydroxyhexadecanoic acid    DHH A
  Glucopyranoside                      33.82      217 (100), 73 (90), 147 (60)                  glucopyranoside                   GPYR
  Unknonwn 17                          34.21      204 (100), 73 (90), 361 (80)                  U17                               
  Unknonwn 18                          34.33      204 (100), 73 (90), 361 (80)                  U18                               
  Unknonwn 19                          34.71      204 (100), 73 (70), 361 (62)                  U19                               
  2,3-Dihydroxy octadecanoic acid      34.95      73 (100), 191 (90), 361 (70)                  2,3-dihydroxy octadecanoic acid   DHO A

TMS = trimethylsilyl derivative.
